<DOC>
	<DOC>NCT02212613</DOC>
	<brief_summary>The purpose of this study is to explore the effects of fixed-dosed brexpiprazole adjunctive treatment in subjects with Major Depressive Disorder with irritability</brief_summary>
	<brief_title>Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>Are 18 to 55 years of age, inclusive, at the time of informed consent with a diagnosis of a single or recurrent, nonpsychotic episode of MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIVTR™) and confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I.) and an adequate clinical psychiatric evaluation Have received a single, trialapproved SSRI or SNRI at an adequate dose for ≥ 6 weeks prior to screening Have a treatment history of inadequate ADT response to at least one ADT (but not &gt; 3) for the current episode. The current major depressive episode must be ≥ 6 weeks in duration. (An inadequate ADT response is defined as &lt; 50% reduction in depressive symptom severity, as measured by subject selfreport on the MGHATRQ.) To be eligible for this trial Have a MADRS Total Score of 20 or more at screening and the Phase A baseline, and have a MADRS Total Score of 18 or more at the Phase B baseline Have no more than 20% improvement in MADRS Total Score at Phase B baseline compared to Phase A baseline Have a score of 6 or more on the KSQ based on the Well being and Reversal Distress Angerhostility subscales at screening, Phase A baseline, and Phase B baseline Have anger attacks as documented by the AAQ at screening, Phase A baseline, and Phase B baseline Are righthanded (defined according to the Edinburgh Handedness Inventory) and have normal hearing and normal/correctedtonormal vision Are willing to discontinue all prohibited psychotropic medications to meet protocolrequired washouts prior to and during the trial period Eligibility confirmed through a telephone SAFER interview with the subject and an independent expert centralized rater Have a current need for involuntary commitment or have been hospitalized within 4 weeks of screening for the current major depressive episode Have a current DSMIVTR Axis I diagnosis of any of the following: delirium, dementia, amnestic, or other cognitive disorders; schizophrenia, schizoaffective disorder, or other psychotic disorders; bipolar I disorder, bipolar II disorder, or bipolar disorder not otherwise specified; eating disorders (including anorexia nervosa or bulimia); obsessive compulsive disorder; panic disorder; or posttraumatic stress disorder Have any of the following current Axis II DSMIVTR diagnoses: borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorders, or mental retardation Experiencing hallucinations, delusions, or any psychotic symptomatology in the current major depressive episode</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Mental Disorders, nonpsychotic episode, antipsychotic</keyword>
	<keyword>Mood Disorder, psychotic disorder</keyword>
</DOC>